WilmerHale Counsels Special Committee of Emisphere Technologies in $1.8B Acquisition by Novo Nordisk

WilmerHale Counsels Special Committee of Emisphere Technologies in $1.8B Acquisition by Novo Nordisk

Client News

Related Solutions

WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
On November 6, Emisphere Technologies, Inc. announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a deal valued at $1.8 billion. Novo Nordisk will acquire Emisphere for $1.35 billion in cash. At the same time, Novo Nordisk has also entered into an agreement to acquire the related royalty stream obligations owed to affiliates of MHR Fund Management LLC for $450 million.

The Board of Directors of Emisphere approved the merger upon the unanimous recommendation of a Special Committee consisting entirely of independent and disinterested Emisphere directors. The deal is subject to customary closing conditions.

The WilmerHale team representing the Special Committee includes Hal Leibowitz and Joseph Conahan.

Read the full press release.  
 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel